Tang Capital Management LLC Purchases Shares of 552,264 AlloVir, Inc. (NASDAQ:ALVR)

Tang Capital Management LLC purchased a new stake in AlloVir, Inc. (NASDAQ:ALVR) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 552,264 shares of the company’s stock, valued at approximately $232,000. Tang Capital Management LLC owned approximately 0.11% of AlloVir as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Gilead Sciences Inc. acquired a new stake in AlloVir in the fourth quarter valued at $6,987,000. Jacobs Levy Equity Management Inc. acquired a new stake in AlloVir in the fourth quarter valued at $279,000. Northern Trust Corp increased its position in shares of AlloVir by 0.8% during the fourth quarter. Northern Trust Corp now owns 159,685 shares of the company’s stock worth $67,000 after purchasing an additional 1,267 shares in the last quarter. Jane Street Group LLC increased its position in shares of AlloVir by 47.8% during the fourth quarter. Jane Street Group LLC now owns 123,159 shares of the company’s stock worth $52,000 after purchasing an additional 39,808 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of AlloVir during the fourth quarter worth about $31,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

AlloVir Stock Performance

ALVR opened at $3.48 on Monday. The business’s 50-day simple moving average is $7.21 and its 200-day simple moving average is $9.87. AlloVir, Inc. has a one year low of $7.96 and a one year high of $24.15. The stock has a market capitalization of $17.55 million, a P/E ratio of -0.17 and a beta of 0.63.

About AlloVir

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.